Antiretroviral compounds and cholesterol efflux from macrophages

Atherosclerosis

Volumn 206, Issue 2, 2009, Pages 439-443

  Mukhamedova, Nigora ^a   Rose, Honor ^a   Cui, Huanhuan L ^a   Grant, Angela ^b   Tchoua, Urbain ^a   Dart, Anthony ^a   Bukrinsky, Michael ^b   Sviridov, Dmitri ^a,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antiretroviral compounds; Atherosclerosis; Cholesterol efflux; Reverse cholesterol transport

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN A1; CHOLESTEROL; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-RETROVIRAL AGENTS; APOPTOSIS; CELL LINE; CHOLESTEROL; CHOLESTEROL, HDL; HIV INFECTIONS; HUMANS; MACROPHAGES; MICE; NELFINAVIR; RITONAVIR;

EID: 70349416637     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.02.042     Document Type: Article

References (18)

1. de Saint Martin L., Vandhuick O., Guillo P., et al. Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis 185 (2006) 361-367
2. Mujawar Z., Rose H., Morrow M.P., et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 4 (2006) e365
3. Shor-Posner G., Basit A., Lu Y., et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 94 (1993) 515-519
4. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356 (2007) 1723-1735
5. Fontas E., van Leth F., Sabin C.A., et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?. J Infect Dis 189 (2004) 1056-1074
6. Bergersen B.M. Cardiovascular risk in patients with HIV infection: impact of antiretroviral therapy. Drugs 66 (2006) 1971-1987
7. Thomas C.M., and Smart E.J. How HIV protease inhibitors promote atherosclerotic lesion formation. Curr Opin Lipidol 18 (2007) 561-565
8. Bukrinsky M., and Sviridov D. HIV and cardiovascular disease: contribution of HIV-infected macrophages to development of atherosclerosis. PLoS Med 4 (2007) e43
9. Rose H., Hoy J., Woolley I., et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis 199 (2008) 79-86
10. Wang X., Mu H., Chai H., et al. Human immunodeficiency virus protease inhibitor ritonavir inhibits cholesterol efflux from human macrophage-derived foam cells. Am J Pathol 171 (2007) 304-314
11. Escher G., Hoang A., Georges S., et al. Demethylation using the epigenetic modifier, 5-azacytidine, increases the efficiency of transient transfection of macrophages. J Lipid Res 46 (2005) 356-365
12. Sviridov D., Pyle L., and Fidge N. Efflux of cellular cholesterol and phospholipid to apolipoprotein A-I mutants. J Biol Chem 271 (1996) 33277-33283
13. Basu S.K., Goldstein J.L., Anderson G.W., and Brown M.S. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci USA 73 (1976) 3178-3182
14. Notari S., Mancone C., Alonzi T., et al. Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF. J Chromatogr B Analyt Technol Biomed Life Sci 863 (2008) 249-257
15. Zhong D.-s., Lu X.-h., Conklin B.S., et al. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol 22 (2002) 1560-1566
16. Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest 110 (2002) 905-911
17. Wassmann S., Wassmann K., and Nickenig G. Regulation of antioxidant and oxidant enzymes in vascular cells and implications for vascular disease. Curr Hypertens Rep 8 (2006) 69-78
18. Vidal F., Domingo J.C., Guallar J., et al. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother 50 (2006) 3824-3832